What is Penpulimab?

Penpulimab (Penpulimab) is a new type of immunotherapy drug that is a programmed death receptor-1 (PD-1) inhibitor. It was jointly developed by Akeso Biopharma and China National Biopharmaceutical Co., Ltd. As a fully humanized IgG1 subtype monoclonal antibody, penpilimab relieves tumor suppression of the immune system by targeting PD-1 molecules on the surface of T cells, thereby reactivating the anti-tumor function of T cells. Different from traditional PD-1 antibodies, penpilimab has been engineered in the Fc segment to effectively reduce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby potentially reducing autoimmune adverse reactions and improving the safety of treatment.

Pembrolizumab has shown promising potential in the treatment of multiple tumor types, including relapsed or refractory classical Hodgkin lymphoma (cHL), recurrent or metastatic nasopharyngeal carcinoma (NPC), and advanced non-small cell lung cancer (NSCLC). In a series of international clinical studies, penpilimab has demonstrated good anti-tumor activity and tolerability, especially in patients who have failed previous treatments, providing a new treatment option. Importantly, in these clinical trials, penpilimab not only demonstrated a high objective response rate (ORR), but also had a relatively low incidence of serious immune-related adverse events (irAEs), giving it a differentiated advantage among similar PD-1 inhibitors.

The mechanism of action of penpilimab is to break the immunosuppressive state in the tumor microenvironment by blocking the binding of PD-1 and its ligands PD-L1 and PD-L2. This process allows T cells to effectively identify and attack cancer cells and restore the body's natural anti-tumor immune response. Compared with some traditional therapies, immunotherapy mobilizes the patient's own immune system to fight instead of directly killing tumor cells, so it has the potential for long-lasting efficacy and a different side effect profile.

Reference materials:https://synapse.patsnap.com/article/what-is-penpulimab-used-for